COVID-19
Valuation Allowance For Deferred Tax Assets: A Quick Guide
ASC 820 compliance sometimes requires a valuation allowance for deferred tax assets. Here’s why—and how valuation allowances are applied.
During COVID-19: Is RPSM The Best Choice For Multinational Companies?
Is RPSM the most appropriate transfer pricing method for multinational companies in the time of COVID-19? Learn about the potential issues here.
The Different Phases Of The “Covid Economy”
Here’s what’s missing in the discussion around COVID-19 and transfer pricing: the long-term view.
Intangible Asset Valuation & Intercompany Sales In The Context Of COVID-19
In light of COVID-19, here’s what multinational businesses should take into account with regard to intangible asset valuation and intercompany transference.
Impact Of COVID-19 On Advance Pricing Agreements With Tax Authorities
Your existing (or pending) advance transfer pricing agreement with tax authorities could be affected by the COVID-19 crisis; here are the issues you should be aware of in the months ahead.
Effects Of COVID-19 On Intercompany Loans
What impact will COVID-19 have on intercompany borrowing? Here’s what to watch out for with regard to intercompany loan interest rates and borrowing practices.
Using Intercompany Service Charges To Share Losses
When it comes to intercompany transactions, accounting for COVID-19 could potentially impact your transfer pricing risk. Here’s what to think about before making changes to intercompany service charges.
Intercompany Agreement Considerations During The COVID-19 Pandemic
Business is not “as usual” in the time of COVID-19; here’s why you should review your intercompany agreements now in light of the new reality, and questions to consider when amending.
